The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs

D. L. van der Velden, L. R. Hoes, H. van der Wijngaart, J. M. van Berge Henegouwen, E. van Werkhoven, P. Roepman, R. L. Schilsky, W. W. J. de Leng, A. D. R. Huitema, B. Nuijen, P. M. Nederlof, C. M. L. van Herpen, D. J. A. de Groot, L. A. Devriese, A. Hoeben, M. J. A. de Jonge, M. Chalabi, E. F. Smit, A. J. de Langen, N. MehraM. Labots, E. Kapiteijn, S. Sleijfer, E. Cuppen, H. M. W. Verheul, H. Gelderblom, E. E. Voest*

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Original languageEnglish
Pages (from-to)127-+
Number of pages16
JournalNature
Volume574
Issue number7776
DOIs
Publication statusPublished - 3 Oct 2019

Keywords

  • CLINICAL-TRIALS
  • OPEN-LABEL
  • PHASE-II
  • RESPONSE ASSESSMENT
  • TARGETED THERAPY
  • 2-STAGE DESIGNS
  • MULTICENTER
  • CRITERIA
  • CANCERS
  • TUMORS

Cite this